David Denning Explained

David W. Denning
Nationality:British
Education:Guy’s Hospital
Known For:Founding president of the Global Action Fund for Fungal Infections
Profession:Physician
Field:Infectious diseases
Work Institutions:
Research Field:Fungal infection

David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at the University of Manchester. He was the founding president, executive director and chief executive of Global Action For Fungal Infections (GAFFI) (2013-2023), which focusses on the global impact of fungal disease.

He became the director of the UK's National Aspergillosis Centre in Manchester, which treats people with chronic pulmonary aspergillosis (CPA), and led the group that produced the first guidelines for CPA in 2016. He retired from clinical practice in 2020.

Career

David Denning studied medicine at Guy’s Hospital, London, and graduated in 1980. He then trained in internal medicine and infectious diseases in London and Glasgow. Between 1985 and 1987, he was a Senior Registrar in Infectious Diseases at Northwick Park Hospital and Medical Research Council research laboratories, before a three-year fellowship in diagnostic microbiology and infectious diseases at Stanford University, which he completed in 1990. He joined the University of Manchester as a Senior Lecturer in 1990.

He became a professor of infectious diseases and global health and medical mycology in 2005 at Wythenshawe Hospital and the University of Manchester.[1] In 2009, he became the director of the UK's National Aspergillosis Centre in Manchester, which treats people with CPA.[2] He is the founding president, executive director and chief executive of the GAFFI, which focusses on the global impact of fungal disease.[1] [3] Denning led the group that produced the first guidelines for CPA in 2016.[4] He chairs the editorial board of a website which focusses on aspergillus and he leads an organisation which provides education on fungal diseases. Antifungal medications that he has contributed to research in include itraconazole, voriconazole, amphotericin B, caspofungin, and micafungin.[1] He founded two spinout biotechnology companies.[5] In 2020, he retired from clinical practice.[5]

Selected publications

Notes and References

  1. Khalaj . Vahid . Professor David W. Denning an Extraordinary High Achiever in Clinical and Translational Science . Iranian Biomedical Journal . September 2018 . 22 . 5 . 290–291 . 10.29252/ibj.22.5.290 . 29397044 . 6058189 . 1028-852X.
  2. Web site: Professor David Denning . The British Society for Antimicrobial Chemotherapy . 20 August 2021 . en.
  3. Web site: David W. Denning FRCP FRCPath FMedSci - Gaffi Gaffi - Global Action For Fungal Infections . gaffi.org . 20 September 2020 . 21 August 2021.
  4. Web site: White . Victoria . World's first clinical guidelines for chronic fungal lung infections . European Pharmaceutical review . 21 August 2021 . 23 December 2015.
  5. Web site: Denning, David . ECMM . 22 August 2021.